# Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome

> **NCT01803724** · — · UNKNOWN · sponsor: **Pontificia Universidad Catolica de Chile** · enrollment: 120 (estimated)

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01803724
- **Lead sponsor:** Pontificia Universidad Catolica de Chile
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2014-06
- **Final completion:** 2014-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803724, "Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01803724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*